Hereditrary Hemorrhagic Telangiectasia (HHT)

Join Sanguine's HHT patient community to stay informed on upcoming trials
Join Sanguine's HHT patient community to stay informed on upcoming trials

We Bring Research To You

Hereditrary Hemorrhagic Telangiectasia (HHT) is a genetic disorder in which abnormal blood vessels form and can affect multiple organs of the body. More than 60,000 people in the U.S. are living with HHT. Better medicine and treatment options are needed for HHT in order to save thousands of people each year.

We believe patients like you are the key to making a difference in HHT research. Joining a research study can help advance the future of HHT research and impact the development of new treatments and cures.

Sanguine's unique model alleviates many of the difficulties associated with clinical trials and we make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel. Sign up to learn more and participate today!

Sanguine's Expertise in Accelerating Research

Members in
our community
Average # of times a
member has participated
Studies completed
by Sanguine

We are currently not recruiting

Stay in touch and we will let you know when the next recruitment is available.

Nationwide Partners

We partner with these like-minded organizations and nonprofits to connect with patients who want to contribute and help accelerate research.


Want to see more? View our full list of Nationwide Partners:

Join the Sanguine community!